Literature DB >> 26906188

Efficacy of 5-aminolevulinic acid based photodynamic therapy in pituitary adenomas-experimental study on rat and human cell cultures.

Lisa Margarete Neumann1, Kerim Beseoglu1, Philipp Joerg Slotty1, Brigitte Senger1, Marcel Alexander Kamp1, Daniel Hänggi2, Hans Jakob Steiger1, Jan Frederick Cornelius3.   

Abstract

BACKGROUND: Incomplete resection of pituitary adenomas may result in recurrence. As adjuvant irradiation is not riskless, alternative treatment options should be investigated. 5-aminolevulinic acid based photodynamic therapy (5-ALA based PDT) showed promising results for malignant gliomas. The present study examined the efficacy of 5-ALA PDT in vitro on benign pituitary adenoma cell cultures.
METHODS: In group I experiments were performed on immortalized rat pituitary adenoma cells (GH3). The cultured cells were treated with different 5-ALA concentrations ranging from 7.5-16.5μg/ml. In Group II human pituitary adenoma cell cultures were obtained from surgically resected adenoma tissue (n=15). These were incubated with 5-ALA concentrations from 12.5-100μg/ml. The concentration ranges had been determined in preliminary dose-finding tests. For both groups incubation time was four hours and PDT was performed by exposition to laser light (635nm, 625s, 18.75J/cm(2)). Cell viability was examined by WST-1 assay.
RESULTS: In both groups PDT showed a 5-ALA concentration-dependent effect on cell death. In group I lower 5-ALA concentrations were necessary to destroy all cells as compared to group II. Moreover, in group II, the different subtypes of human adenomas showed different sensitivities to 5-ALA-based PDT (secreting vs. non-secreting). Especially corticotroph adenomas were highly sensitive to 5-ALA PDT.
CONCLUSIONS: The GH3 cell line was an useful in vitro model to optimize different PDT parameters. Human pituitary adenoma cells could also be killed by 5-ALA PDT, however this required higher 5-ALA concentrations. Furthermore, the results suggested different 5-ALA sensitivities between different human adenoma cell types. More experiments are necessary to confirm these preliminary results.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  5-ALA; PDT; Photodynamic therapy; Pituitary adenoma; Recurrence

Mesh:

Substances:

Year:  2016        PMID: 26906188     DOI: 10.1016/j.pdpdt.2016.02.006

Source DB:  PubMed          Journal:  Photodiagnosis Photodyn Ther        ISSN: 1572-1000            Impact factor:   3.631


  5 in total

1.  Use of optical fluorescence agents during surgery for pituitary adenomas: current state of the field.

Authors:  Stephanie W Chang; Daniel A Donoho; Gabriel Zada
Journal:  J Neurooncol       Date:  2018-12-06       Impact factor: 4.130

Review 2.  Fluorescence guided surgery for pituitary adenomas.

Authors:  Nikita Lakomkin; Jamie J Van Gompel; Kalmon D Post; Steve S Cho; John Y K Lee; Constantinos G Hadjipanayis
Journal:  J Neurooncol       Date:  2021-02-21       Impact factor: 4.130

Review 3.  Fluorophores Use in Pituitary Surgery: A Pharmacokinetics and Pharmacodynamics Appraisal.

Authors:  Daniele Bongetta; Fulvio Tartara; Fabio Pagella; Teresa Somma; Marilou Cavaliere; Giuseppe Di Perna; Francesco Zenga; Fabio Cofano; Diego Garbossa; Cesare Zoia
Journal:  Brain Sci       Date:  2021-04-28

4.  5-Aminolaevulinic Acid-Based Photodynamic Therapy Restrains Pathological Hyperplasia of Fibroblasts.

Authors:  Xiaochuan Wang; Ping Cao; Jian Liu; Peng Du; Zhiqiong Wang; Wei Chen; Chang Liu; Yifei Wu
Journal:  Med Sci Monit       Date:  2017-01-04

5.  Radiodynamic therapy with CsI(na)@MgO nanoparticles and 5-aminolevulinic acid.

Authors:  Fangchao Jiang; Chaebin Lee; Weizhong Zhang; Wen Jiang; Zhengwei Cao; Harrison Byron Chong; Wei Yang; Shuyue Zhan; Jianwen Li; Yong Teng; Zibo Li; Jin Xie
Journal:  J Nanobiotechnology       Date:  2022-07-16       Impact factor: 9.429

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.